EGFR and non-small cell lung carcinoma: In PDAC, the only approved repurposed targeted therapy in combination with GEM is Erlotinib, a small molecule EGFR inhibitor initially developed for non-small cell lung cancer (NSCLC) (Kelley and Ko, 2008).